Advisory Alpha’s Takeda Pharmaceutical TAK Stock Holding History

Advisory Alpha’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-442	Closed	-$8K	–	582
2020 Q3	$8K	Buy	+442	New	+$8.05K	﹤0.01%	457

Other funds holding TAK

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Advisory Alpha's TAK Position: Q4 2020 in Review

Advisory Alpha sold out of Takeda Pharmaceutical (TAK) in Q4 2020, closing a stake of 442 shares — an estimated $8K sold.

Advisory Alpha first reported a position in TAK in Q3 2020 and held it in 1 quarter. The position peaked at $8K in Q3 2020. 312 funds tracked by Wall St. Rank hold TAK as of Q4 2020.

Advisory Alpha reported no remaining Takeda Pharmaceutical position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 442 Takeda Pharmaceutical shares in Q4 2020, an estimated $8K.
Advisory Alpha first reported a position in Takeda Pharmaceutical in Q3 2020 and held it in 1 quarter.
Advisory Alpha's Takeda Pharmaceutical position peaked at $8K in Q3 2020.
312 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.